FDA Approves IMFINZI Plus Carboplatin and Paclitaxel for Certain Patients With Endometrial Cancer - European Medical Journal

This site is intended for healthcare professionals

Continue

FDA Approves IMFINZI Plus Carboplatin and Paclitaxel for Certain Patients With Endometrial Cancer

Oncology

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.